Sublingual nitroglycerin 0.4 mg significantly decreased cardiovagal baroreflex sensitivity (12.9 to 7.1 ms/mmHg) and increased sympathetic baroreflex sensitivity (0.8 to 1.5) (P<0.05).
Does sublingual nitroglycerin 0.4 mg modulate cardiovagal and sympathetic baroreflex sensitivity in healthy subjects?
Sublingual nitroglycerin acutely increases muscle sympathetic nerve activity through a decrease in cardiovagal baroreflex sensitivity and an increase in sympathetic baroreflex sensitivity.
p-value: p=<0.05
The effects of nitroglycerin (glyceryl trinitrate, GTN) on baroreflex sensitivity (BRS) are incompletely understood. Moreover, there are no reports evaluating the acute responses in both the sympathetic BRS (SBRS) and the cardiovagal BRS (CBRS) to the administration of sublingual GTN. We hypothesized that sublingual GTN modulates both CBRS and SBRS. In 10 healthy subjects, beat-to-beat heart rate (HR), blood pressure (BP), and muscle sympathetic nerve activity (MSNA) were recorded before and for 10 min after sublingual administration of GTN 0.4 mg. SBRS was evaluated from the relationship between spontaneous variations in diastolic BP and MSNA. CBRS was assessed with the sequence technique. These variables were assessed during baseline, during 3rd–6th min ( post A), and 7th–10th min ( post B) after GTN administration. Two min after GTN administration, MSNA increased significantly and remained significantly elevated during recording. Compared with baseline, CBRS decreased significantly ( post A: 12.9 ± 1.6 to 7.1 ± 1.0 ms/mmHg, P < 0.05), whereas SBRS increased significantly ( post A: 0.8 ± 0.2 to 1.5 ± 0.2 units·beat −1 ·mmHg −1 , P < 0.05) with an upward shift of the operating point. There were no differences in these variables between posts A and B. A clinical dose of GTN increased MSNA rapidly through effects on both CBRS and SBRS. These effects should be kept in mind when nitrates are used to clinically treat chest pain and acute coronary syndromes and used as vasodilators in experimental settings.
Hamaoka et al. (Wed,) conducted a other in Healthy (n=10). Sublingual nitroglycerin vs. Baseline was evaluated on Cardiovagal baroreflex sensitivity (CBRS) and sympathetic baroreflex sensitivity (SBRS) (p=<0.05). Sublingual nitroglycerin 0.4 mg significantly decreased cardiovagal baroreflex sensitivity (12.9 to 7.1 ms/mmHg) and increased sympathetic baroreflex sensitivity (0.8 to 1.5) (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: